Packer, Milton; Butler, Javed; Filippatos, Gerasimos S; Jamal, Waheed; Salsali, Afshin; Schnee, Janet; Kimura, Karen; Zeller, Cordula; George, Jyothis; Bocchi, Edimar Alcides 
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, PROTEÍNAS DE TRANSPORTE, MORBIDADE, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, GLICOSÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PACKER, Milton et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. European journal of heart failure, v. 21, n. 10, p. 1270-1278, 2019Tradução . . Disponível em: https://doi.org/10.1002/ejhf.1536. Acesso em: 06 nov. 2024.APA
Packer, M., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J., et al. (2019). Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. European journal of heart failure, 21( 10), 1270-1278. doi:10.1002/ejhf.1536NLM
Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Bocchi EA. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial [Internet]. European journal of heart failure. 2019 ; 21( 10): 1270-1278.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1002/ejhf.1536Vancouver
Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Bocchi EA. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial [Internet]. European journal of heart failure. 2019 ; 21( 10): 1270-1278.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1002/ejhf.1536
